TY - JOUR
T1 - Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort
T2 - A Gynecologic Oncology Group study
AU - Wenzel, Lari
AU - Huang, Helen Q.
AU - Cella, David
AU - Walker, Joan L.
AU - Armstrong, Deborah K.
N1 - Funding Information:
This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the GOG Statistical Office (CA 37517).
PY - 2008/7
Y1 - 2008/7
N2 - Objective: To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer. Methods: A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3-6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to abdominal discomfort grading. Results: Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00-0.44. This subscale was able to distinguish those graded to have physician-rated abdominal pain compared to those without clinician-reported discomfort. Conclusion: The four-item AD subscale reliably and validly assesses ovarian cancer-specific abdominal discomfort, and captures abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.
AB - Objective: To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer. Methods: A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3-6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to abdominal discomfort grading. Results: Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00-0.44. This subscale was able to distinguish those graded to have physician-rated abdominal pain compared to those without clinician-reported discomfort. Conclusion: The four-item AD subscale reliably and validly assesses ovarian cancer-specific abdominal discomfort, and captures abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.
KW - Abdominal discomfort
KW - Measurement tool
KW - Self-assessment
UR - http://www.scopus.com/inward/record.url?scp=45549087804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45549087804&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2008.02.011
DO - 10.1016/j.ygyno.2008.02.011
M3 - Article
C2 - 18430468
AN - SCOPUS:45549087804
SN - 0090-8258
VL - 110
SP - 60
EP - 64
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -